Shares of InMed Pharmaceuticals INM surged 36.33% at market close after the company announced the launch of its neurodegenerative disease program (INM-900 series), to investigate the effects of ...
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of ...
VANCOUVER, May 14, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its ...
InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease
InMed Pharmaceuticals (Nasdaq:INM) recently released preclinical data indicating its proprietary, small molecule compound, INM-901, targets multiple biological pathways associated with Alzheimer’s ...
Transition to INM-755 Expected to Improve the Probability of Development and Regulatory Success Initiation of a Phase I Clinical Trial Remains On-track TSX:IN OTCQX:IMLFF VANCOUVER, March 13, 2019 ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from InMed ...
Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials Consistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results